Panangin - instructions for use, dose, side effects, contraindications

Silicon dioxide, colloidal - 2.00 mg, povidone - 3.30 mg magnesium stearate - 4.00 mg talc - 10.00 mg maize starch - 86,10 mg, potato starch - 3.30 mg per tablet core .

Shell composition:

Macrogol 6000 - 1.40 mg, titanium dioxide Cv. ind. 77891, E171 - 5.30 mg, methacrylic acid copolymer E 100% - 6.00 mg, talc - 7.30 mg.

Description:

Round biconvex tablets covered with a film coat, white or almost white, with a slightly shiny and uneven surface, almost odorless.

Pharmacotherapeutic group:Potassium and magnesium preparation

ATX: & nbsp

A.12.C.X Preparations of other minerals

Pharmacodynamics:ATThe most important intracellular cations of K⁺ and Mg⁺⁺ play a key role in the functioning of numerous enzymes, in the formation of bonds between macromolecules and intracellular structures and in the mechanism of muscle contractility.The intra- and extracellular ratio of potassium, calcium, sodium and magnesium ions has an effect on myocardial contractility. Endogenous aspartate acts as an ion conductor: it has a high affinity for cells, due to the insignificant dissociation of its salts, the ions enter the cell in the form of complex compounds. Aspartates of magnesium and potassium improve myocardial metabolism. The lack of magnesium / potassium predisposes to the development of hypertension, coronary artery atherosclerosis, arrhythmias and metabolic changes in the myocardium.

Pharmacokinetics:Absorption is high. It is excreted by the kidneys.

Indications:

As an additional tool in the treatment of chronic heart diseases (heart failure, condition after myocardial infarction), heart rhythm disturbances (primarily ventricular arrhythmias), with digitalis treatment; Substitution therapy with a deficiency of magnesium / potassium in food.

Contraindications:

Hypersensitivity to any of the components of the drug, acute and chronic renal failure, hyperkalemia, hypermagnesia, Addison's disease, atrioventricular blockade I-III degree, cardiogenic shock (arterial pressure less than 90 mm Hg), impaired metabolism of amino acids, severe myasthenia gravis, hemolysis, acute metabolic acidosis, dehydration.

Pregnancy and lactation:Pregnancy (especially in the first trimester) and during lactation.

Dosing and Administration:

Before use, consult a physician.

Inside, the drug should be used after meals, tk. The acidic environment of the stomach reduces its effectiveness.

Usual daily dose: 1-2 tablespoons. 3 times a day. The maximum daily dose: 3 tablets 3 times a day.

The duration of the drug and the need for repeated courses is determined by the doctor.

Side effects:

Possible nausea, vomiting, diarrhea, discomfort or burning sensation in the pancreas (in patients with an anatomic gastritis or cholecystitis), atrioventricular blockade, paradoxical reaction (increase in the number of extrasystoles), hyperkalemia (nausea, vomiting, diarrhea, parasthesia), hypermagnia (red face, thirst, lowering blood pressure, hyporeflexia, respiratory depression, convulsions).

Overdose:

Symptoms: conduction disturbance (especially with previous pathology of the conduction systemheart).

Treatment: intravenous calcium chloride; if necessary, hemodialysis and peritoneal dialysis.

Interaction:

Pharmacodynamic: joint application with potassium-sparing diuretics (triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, angiotensin converting enzyme (ACE) inhibitors, non-steroidal anti-inflammatory drugs increases the risk of hyperkalemia up to the development of arrhythmia and asystole. The use of potassium preparations together with glucocorticosteroids eliminates the hypokalemia caused by the latter. Under the influence of potassium, undesirable effects of cardiac glycosides decrease. Strengthens the negative dromo- and batmotropic effect of antiarrhythmic drugs. Magnesium reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin. Anesthetics increase the oppressive effect of magnesium preparations on the central nervous system; when used simultaneously with atrakuronium, decamethonium, succinyl chloride and suxamethonium, neuromuscular blockade may be strengthened; calcitriol increases the content of magnesium in blood plasma, calcium preparations reduce the effect of magnesium preparations.

Pharmacokinetic: astringent and enveloping agents reduce the absorption of the drug in the gastrointestinal tract and it is necessary to observe a three-hour interval between ingestion of Panangin with the listed agents.

Special instructions:

Particular attention is required by patients with diseases accompanied by hyperkalemia: regular monitoring of the ionogram is necessary.

Effect on the ability to drive transp. cf. and fur:Does not affect the ability to drive a car and engage in activities that require increased concentration and speed of psychomotor reactions.

Form release / dosage:

Film coated tablets.

Packaging:

For 50 tablets in a polypropylene vial. 1 bottle in a cardboard box with instructions for use.

Storage conditions:

At a temperature of 15-30 ° C. Keep out of the reach of children.

Shelf life:

5 years.

Do not use the drug after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:П N013093 / 02

Date of registration:13.08.2007

The owner of the registration certificate:GEDEON RICHTER, OJSC GEDEON RICHTER, OJSC Hungary

Manufacturer: & nbsp

GEDEON RICHTER, Plc. Hungary

GEDEON RICHTER-RUS, CJSC Russia

Representation: & nbspGEDEON RICHTER OJSC GEDEON RICHTER OJSC Hungary

Information update date: & nbsp22.09.2014

Illustrated instructions

Instructions

Panangin® (Panangin®)